Document is current
Any future updates will be listed below
-
Authors
Rana, Masooma Shifa https://orcid.org/0000-0003-1731-085X
Fernandez-Pol, Sebastian
Jensen, Alexandria https://orcid.org/0000-0001-6337-9079
Hovanky, Vanna
Velayati, Arash
Oak, Jean S.
Silva, Oscar
Ames, Erik
Muffly, Lori S. https://orcid.org/0000-0002-9887-6136
Sahaf, Bita
Arai, Sally https://orcid.org/0000-0003-1993-4172
Kennedy, Vanessa E.
Bharadwaj, Sushma
Iberri, David J.
Liedtke, Michaela
Natkunam, Yasodha https://orcid.org/0000-0002-9816-1018
Shiraz, Parveen https://orcid.org/0000-0002-6721-0358
Weng, Wen-Kai
Smith, Melody
Frank, Matthew J.
Mackall, Crystal L.
Dahiya, Saurabh
Mikkilineni, Lekha
Miklos, David B. https://orcid.org/0000-0003-0717-4305
Hosoya, Hitomi
Sidana, Surbhi https://orcid.org/0000-0003-3288-7614
- License Information
-
More Information
Article History
Received: 16 August 2025
Revised: 30 January 2026
Accepted: 12 March 2026
First Online: 4 April 2026
Competing interests
: SS reports Research Funding: BMS, Janssen, Novartis, AbbVie. Consultancy/Advisory board: BMS, Janssen, Sanofi, Takeda, Regeneron, AbbVie, Pfizer, BiolineRx, Legend, Kite, Arcellx, Genentech, Roche. CLM is a founder, Board Member, equity holder and consultant for Link Cell Therapies, has received consulting fees from CARGO, Ensoma, AstraZeneca, Immatics, RedTree Venture Capital, Grace Science, GBM NewCo, and Nektar, and research funding from Tune Therapeutics. YN: Advisory board Roche and Leica Biosystems; grant funding Roche & Kite Pharma. SD: Research funding from Kite, a Gilead Company and Kyverna Therapeutics. Consulting/advisory role for Adaptive Biotechnologies, Incyte, and Bristol Myers Squibb, Kite Gilead, Johnson and Johnson. DBM reports consulting/advisory roles for Adaptive Biotechnologies, Adicet, AlloGene, Janssen, Juno-Celgene-BMS, Kite-Gilead, Miltenyi Biotech, Novartis, Pharmacyclics LLC, an AbbVie Company, Precision Bioscience, and Takeda; and reports research funding from 2seventy bio, Adaptive Biotechnologies, Adicet Bio, AlloGene, Pharmacyclics LLC, an AbbVie Company, Genentech, Kite-Gilead, Miltenyi Biotech, Novartis, and Roche.
: This study was conducted in accordance with all relevant institutional guidelines and regulations. The study protocol was approved by the Stanford University Institutional Review Board (IRB-43375; approved September 2025). All participants provided written informed consent prior to inclusion in the study.
